Mohammed Jaloudi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed Jaloudi has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Alex Agelidis
Scripps Cancer Center, Scripps Health, La Jolla, California, USA
3 shared publicationsAnna Ter-Zakarian
Scripps Cancer Center, Scripps Health, La Jolla, California, USA
3 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 877-881
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond [Response to Letter]
Response to Letter in regards to Triple-Negative Breast Cancer on the Rise or…? [Letter]
- 1 September 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 877-881
Open AccessTriple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond [Response to Letter]
Response to Letter in regards to Triple-Negative Breast Cancer on the Rise or…? [Letter]
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 567-572
Male Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment
Male breast cancer (MBC) is a rare condition, comprising less than 1% of all breast cancer cases. This review examines the epidemiology, risk factors, clinical presentation, diagnostic approaches, and treatment strategies for MBC in both early and advanced stages. Early diagnosis of MBC poses a significant challenge, as men typically present with more advanced disease than women with breast cancer, likely due to limited awareness and delayed medical care. Data guiding treatment strategies remain limited, as most clinical trials have historically excluded male participants. This review provides a comprehensive analysis of recent advances in MBC, critically examines current diagnostic and therapeutic gaps, and outlines emerging research priorities. By emphasizing the limitations of existing evidence and the urgent need for male-specific clinical trials, this manuscript presents a forward-looking perspective aimed at fostering more inclusive research to develop tailored, evidence-based strategies for male patients.
- 1 July 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 567-572
Open AccessMale Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment
Male breast cancer (MBC) is a rare condition, comprising less than 1% of all breast cancer cases. This review examines the epidemiology, risk factors, clinical presentation, diagnostic approaches, and treatment strategies for MBC in both early and advanced stages. Early diagnosis of MBC poses a significant challenge, as men typically present with more advanced disease than women with breast cancer, likely due to limited awareness and delayed medical care. Data guiding treatment strategies remain limited, as most clinical trials have historically excluded male participants. This review provides a comprehensive analysis of recent advances in MBC, critically examines current diagnostic and therapeutic gaps, and outlines emerging research priorities. By emphasizing the limitations of existing evidence and the urgent need for male-specific clinical trials, this manuscript presents a forward-looking perspective aimed at fostering more inclusive research to develop tailored, evidence-based strategies for male patients.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 523-529
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Triple-negative breast cancer (TNBC) represents a particularly aggressive and heterogeneous subtype of breast cancer, associated with poor prognosis and limited treatment options. This review delves into the rising incidence of TNBC, particularly among younger women, and explores the significant demographic disparities that contribute to variations in incidence, treatment access and survival outcomes. We provide a discussion of TNBC’s molecular and genetic landscape, including key pathways revolving around TP53, BRCA1/2 mutations, and PI3K/AKT signaling, which have informed the development of targeted therapies. Recent practice-changing studies are highlighted, which have resulted in the integration of immune checkpoint inhibitors in both early-stage and metastatic settings, the application of PARP inhibitors for BRCA-mutated TNBC and the introduction of antibody-drug conjugates as valuable new therapeutic options. We also review the role of neoadjuvant chemotherapy, novel biomarkers such as tumor-infiltrating lymphocytes, and advancements in diagnostic tools, including machine learning-based imaging and spatial transcriptomics, which are all driving shifts towards personalized approaches. This review synthesizes emerging research and major changes in clinical practice to provide a concise overview of the recent innovations and upcoming trends in TNBC diagnosis and therapy.
- 1 June 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 523-529
Open AccessTriple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Triple-negative breast cancer (TNBC) represents a particularly aggressive and heterogeneous subtype of breast cancer, associated with poor prognosis and limited treatment options. This review delves into the rising incidence of TNBC, particularly among younger women, and explores the significant demographic disparities that contribute to variations in incidence, treatment access and survival outcomes. We provide a discussion of TNBC’s molecular and genetic landscape, including key pathways revolving around TP53, BRCA1/2 mutations, and PI3K/AKT signaling, which have informed the development of targeted therapies. Recent practice-changing studies are highlighted, which have resulted in the integration of immune checkpoint inhibitors in both early-stage and metastatic settings, the application of PARP inhibitors for BRCA-mutated TNBC and the introduction of antibody-drug conjugates as valuable new therapeutic options. We also review the role of neoadjuvant chemotherapy, novel biomarkers such as tumor-infiltrating lymphocytes, and advancements in diagnostic tools, including machine learning-based imaging and spatial transcriptomics, which are all driving shifts towards personalized approaches. This review synthesizes emerging research and major changes in clinical practice to provide a concise overview of the recent innovations and upcoming trends in TNBC diagnosis and therapy.